July 15th 2020
press releases
June 29th 2020
press releases
June 22nd 2020
press releases
This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.
June 3rd 2020
analyst reports
For a copy of this research report please contact tnjain@bellpotter.com.au
June 3rd 2020
analyst reports
June 2nd 2020
analyst reports
Upcoming Events
Whats next.
September 18th 2020 - September 22nd 2020
read more
October 26th 2020 - October 28th 2020
read more
passion.
It takes a great deal of passion on the fight against cancer. We put our heart and soul into winning it.
know-how.
Our goal is to gather the strongest forces, the brightest minds and the most dedicated employees.
research.
Accurate research is the strong foundation for developing potential in effective treatment.
What is LAG3?
Lymphocyte-activation gene 3, or LAG-3 (LAG3), is a cell surface molecule with biologic effects on T cell function.
LAG3 is being used for many cancer immunotherapy treatments including Eftilagimod Alpha from Immutep.
